A study of 3clpros as promising targets against sars-cov and sars-cov-2
- 주제(키워드) Antiviral , Drug repurposing , FRET , Inhibitory compounds , SARS-CoV-2 3CL protease
- 후원정보 Shin, D.H.; Graduate School of Pharmaceutical Sciences, 52, Ewhayeodae-gil, South Korea; email: dhshin@ewha.ac.kr
- 등재 SCIE, SCOPUS
- 발행기관 MDPI AG
- 발행년도 2021
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000181732
- 본문언어 영어
- Published As http://dx.doi.org/10.3390/microorganisms9040756
초록/요약
The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), results in serious chaos all over the world. In addition to the available vaccines, the development of treatments to cure COVID-19 should be done quickly. One of the fastest strategies is to use a drug-repurposing approach. To provide COVID-19 patients with useful information about medicines currently being used in clinical trials, twenty-four com-pounds, including antiviral agents, were selected and assayed. These compounds were applied to verify the inhibitory activity for the protein function of 3CLpros (main proteases) of SARS-CoV and SARS-CoV-2. Among them, viral reverse-transcriptase inhibitors abacavir and tenofovir revealed a good inhibitory effect on both 3CLpros. Intriguingly, sildenafil, a cGMP-specific phosphodiesterase type 5 inhibitor also showed significant inhibitory function against them. The in silico docking study suggests that the active-site residues located in the S1 and S2 sites play key roles in the interactions with the inhibitors. The result indicates that 3CLpros are promising targets to cope with SAR-CoV-2 and its variants. The information can be helpful to design treatments to cure patients with COVID-19. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
more